PRKCI

Across TCGA pan-cancer cohorts, PRKCI Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRKCI data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher PRKCI Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRKCI expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

LUSC, BLCA, and LUAD are the cancer types where PRKCI Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.218	0.631	.025	15	view →
BLCA	OS	Median	II,III,IV	1.000	0.408	.019	12	view →
LUAD	OS	Median	III,IV	0.240	0.687	.003	12	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	II,III,IV	0.915	0.438	.033	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRKCI–LUSC (OS)

Open the LUSC breakdown →